Lupin gets positive result for Solosec phase 3 clinical trial
On Monday, Lupin informed the bourses about the positive top-line results from its pivotal Phase 3 clinical trial to assess the efficacy and safety of single-dose Solosec (Secnidazole) 2g oral granules in 147 female patients with trichomoniasis by its US-based subsidiary. Solosec is approved by USFDA to treat bacterial vaginosis (BV) in women.
Trichomoniasis is the most common non-viral, curable, sexually transmitted infection (STI) in USA. The company's management said that Trichomoniasis impacts an estimated three to five million people in USA.
Lupin plans to submit a supplemental new drug application for Solosec to USFDA for the treatment of trichomoniasis in the second half of 2020.
On Tuesday, the stock of Lupin opens gap-up at Rs 858 as against its previous close of Rs 841.1 and touched an intraday high of Rs 863.9. However, later, it cooled down and at 11.21 am, the stock was trading at Rs 843.